Exelixis and Takeda win Japanese approval for CABOMETYX in renal cell carcinoma

Aug. 25, 2021 4:39 PM ETExelixis, Inc. (EXEL), TAKBy: Dulan Lokuwithana, SA News Editor16 Comments
  • Exelixis (NASDAQ:EXEL) and Takeda (NYSE:TAK) announced that the two companies along with their partner Ono Pharmaceutical received the regulatory approval for CABOMETYX (cabozantinib) in combination with OPDIVO (nivolumab) as a treatment of unresectable or metastatic renal cell carcinoma (RCC).
  • Previously, the oral

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.